At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BBLG Bone Biologics Corp
Trading 12-19 13:13:24 EST
1.04
+0.01
+0.49%
High1.05
Low1.03
Vol27.78K
Open1.04
D1 Closing1.03
Amplitude1.94%
Mkt Cap2.55M
Tradable Cap2.45M
Total Shares2.46M
T/O28.85K
T/O Rate1.17%
Tradable Shares2.37M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Bone Biologics Corp reports results for the quarter ended September 30 - Earnings Summary
OTC Markets Hosts Virtual Investor Presentation with Jeff Frelick, CEO and President of Bone Biologics, and Deina Walsh, CFO, with Brad Sorensen, Senior Analyst at Zacks SCR
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.